Tumor Necrosis Factor Receptor Type II is an inhibitor of TNF and can block TNF bioactivity. Recombinant human TNF-RII produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of the extraCellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of TNFRII contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. Potency is determined by its ability to neutralize TNF-α mediated growth inhibition of A375 cells, corresponding to a Specific Activity of 1.7 x 10⁷ IU/mg.
References:
See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.